Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cicrotoic Acid SCHEMBL2773332 | 1.00 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| Cicrotoic Acid SCHEMBL2773334 | 1.00 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL13468227 | 0.98 | CES2 (0.40) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL13468214 | 0.93 | CES2 (0.35) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL3139362 | 0.88 | — | — | |
| SCHEMBL12491769 | 0.88 | — | — | |
| SCHEMBL3139365 | 0.88 | — | — | |
| SCHEMBL9609535 | 0.84 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL11871555 | 0.82 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL11871558 | 0.82 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-120020252-A | SiRNA for inhibiting LPA expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| WO-2008055254-A2 | FORMULATIONS AND METHODS FOR ORAL DELIVERY OF PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-08 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-120020252-A | SiRNA for inhibiting LPA expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240124889-A1 | COMPOSITIONS AND METHODS FOR THE VECTORED AUGMENTATION OF PROTEIN DESTRUCTION, EXPRESSION AND/OR REGULATION | VOYAGER THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | CES2 179/4885CES1 779/4885HDAC8 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.